Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Timothy Craig, Avner Reshef, H Henry Li, Joshua Jacobs, Jonathan A. Bernstein, Henriette Farkas, William H. Yang, Erik S.G. Stroes, Isao Ohsawa, Raffi Tachdjian, Michael Manning, William R. Lumry, Inmaculada Martinez Saguer, Emel Aygören‐Pürsün, Bruce Ritchie, Gordon Sussman, John Anderson, Kimito Kawahata, Yusuke Suzuki, Petra Staubach, Regina Treudler, Henrike Feuersenger, Fiona Glassman, Iris Jacobs, Markus Magerl